A5027810898- Digital Mental Health Interventions
- Multiple Sclerosis Research Studies
- Autism Spectrum Disorder Research
- Telemedicine and Telehealth Implementation
- Cystic Fibrosis Research Advances
Institut Dr. Schauerte
2021-2022
Background: In patients with multiple sclerosis (MS), non-adherence to disease-modifying drug therapy is associated an increased rate of MS relapses. Early identification at risk would allow provision timely and individualized support. The aim the BETAPREDICT study was investigate potential predictors adherence in Germany treated interferon β-1b (IFNβ-1b) using BETACONNECT® autoinjector. Methods: a national, multi-center, prospective, non-interventional, single-arm, 24-month cohort...
Background The BETACONNECT autoinjector and myBETAapp app were designed to support patients with multiple sclerosis receiving interferon β-1b are an ideal platform for digital observational studies. A recent pilot study in Germany demonstrated the feasibility of using recruit patients, obtain informed consent, evaluate medication-taking behavior over 6 months. Objective This aims describe 1 year based on data collected from provide information patient-reported outcomes (PROs). optional use...
<sec> <title>UNSTRUCTURED</title> N/A </sec>
<sec> <title>BACKGROUND</title> The BETACONNECT autoinjector and myBETAapp app were designed to support patients with multiple sclerosis receiving interferon β-1b are an ideal platform for digital observational studies. A recent pilot study in Germany demonstrated the feasibility of using recruit patients, obtain informed consent, evaluate medication-taking behavior over 6 months. </sec> <title>OBJECTIVE</title> This aims describe 1 year based on data collected from provide information...